High-risk clinicopathological features and their predictive significance in Korean patients with stage II colon cancer

Ji Soo Park, Hong Jae Chon, Hei Cheul Jeung, Sang Joon Shin, SunYoung Rha, Joong Bae Ahn, Kang Young Lee, Namkyu Kim, Hyuncheol Chung

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose: We investigated the prognostic factors for recurrence in Korean patients with stage II colon cancer and evaluated their predictive significance with 5-fluorouracil (FU)-based adjuvant chemotherapy. Methods: We analyzed the relationship between clinicopathological features and relapse-free survival (RFS) of 716 stage II colon cancer patients who underwent curative resection. Predictive values were assessed using 5-year RFS and 5-year cancer-specific survival (CSS). Results: The 5-year RFS, 5-year CSS, 5-year disease-free survival, and 5-year overall survival rates were 87.4, 94.9, 84.8, and 90.5 %, respectively. T4 stage (hazard ratio [HR], 2.342; 95 % confidence interval [CI], 1.348–4.068; p = 0.003), preoperative bowel obstruction or perforation (HR 2.428; 95 % CI 1.241–4.752; p = 0.010), and age older than 70 years (HR 1.740; 95 % CI 1.130–2.678; p = 0.012) were poor prognostic factors for recurrence in multiple Cox regression analyses. In 60 patients with T4 disease, 5-FU-based adjuvant chemotherapy was associated with improved 5-year CSS of the patients (90.3 vs. 46.7 %; HR 0.135; 95 % CI 0.035–0.517; p = 0.003). Conclusions: We found discordance between the risk factors for recurrence and the predictive value for 5-FU-based adjuvant chemotherapy in Korean patients with stage II colon cancer. Future prospective clinical trials selectively targeting high-risk patients are needed.

Original languageEnglish
Pages (from-to)2051-2059
Number of pages9
JournalJournal of cancer research and clinical oncology
Volume142
Issue number9
DOIs
Publication statusPublished - 2016 Sep 1

Fingerprint

Colonic Neoplasms
Recurrence
Survival
Adjuvant Chemotherapy
Fluorouracil
Confidence Intervals
Neoplasms
Disease-Free Survival
Survival Rate
Regression Analysis
Clinical Trials

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Park, Ji Soo ; Chon, Hong Jae ; Jeung, Hei Cheul ; Shin, Sang Joon ; Rha, SunYoung ; Ahn, Joong Bae ; Lee, Kang Young ; Kim, Namkyu ; Chung, Hyuncheol. / High-risk clinicopathological features and their predictive significance in Korean patients with stage II colon cancer. In: Journal of cancer research and clinical oncology. 2016 ; Vol. 142, No. 9. pp. 2051-2059.
@article{4c758a72e6054772ae781b721ee7adb7,
title = "High-risk clinicopathological features and their predictive significance in Korean patients with stage II colon cancer",
abstract = "Purpose: We investigated the prognostic factors for recurrence in Korean patients with stage II colon cancer and evaluated their predictive significance with 5-fluorouracil (FU)-based adjuvant chemotherapy. Methods: We analyzed the relationship between clinicopathological features and relapse-free survival (RFS) of 716 stage II colon cancer patients who underwent curative resection. Predictive values were assessed using 5-year RFS and 5-year cancer-specific survival (CSS). Results: The 5-year RFS, 5-year CSS, 5-year disease-free survival, and 5-year overall survival rates were 87.4, 94.9, 84.8, and 90.5 {\%}, respectively. T4 stage (hazard ratio [HR], 2.342; 95 {\%} confidence interval [CI], 1.348–4.068; p = 0.003), preoperative bowel obstruction or perforation (HR 2.428; 95 {\%} CI 1.241–4.752; p = 0.010), and age older than 70 years (HR 1.740; 95 {\%} CI 1.130–2.678; p = 0.012) were poor prognostic factors for recurrence in multiple Cox regression analyses. In 60 patients with T4 disease, 5-FU-based adjuvant chemotherapy was associated with improved 5-year CSS of the patients (90.3 vs. 46.7 {\%}; HR 0.135; 95 {\%} CI 0.035–0.517; p = 0.003). Conclusions: We found discordance between the risk factors for recurrence and the predictive value for 5-FU-based adjuvant chemotherapy in Korean patients with stage II colon cancer. Future prospective clinical trials selectively targeting high-risk patients are needed.",
author = "Park, {Ji Soo} and Chon, {Hong Jae} and Jeung, {Hei Cheul} and Shin, {Sang Joon} and SunYoung Rha and Ahn, {Joong Bae} and Lee, {Kang Young} and Namkyu Kim and Hyuncheol Chung",
year = "2016",
month = "9",
day = "1",
doi = "10.1007/s00432-016-2208-2",
language = "English",
volume = "142",
pages = "2051--2059",
journal = "Journal of Cancer Research and Clinical Oncology",
issn = "0171-5216",
publisher = "Springer Verlag",
number = "9",

}

High-risk clinicopathological features and their predictive significance in Korean patients with stage II colon cancer. / Park, Ji Soo; Chon, Hong Jae; Jeung, Hei Cheul; Shin, Sang Joon; Rha, SunYoung; Ahn, Joong Bae; Lee, Kang Young; Kim, Namkyu; Chung, Hyuncheol.

In: Journal of cancer research and clinical oncology, Vol. 142, No. 9, 01.09.2016, p. 2051-2059.

Research output: Contribution to journalArticle

TY - JOUR

T1 - High-risk clinicopathological features and their predictive significance in Korean patients with stage II colon cancer

AU - Park, Ji Soo

AU - Chon, Hong Jae

AU - Jeung, Hei Cheul

AU - Shin, Sang Joon

AU - Rha, SunYoung

AU - Ahn, Joong Bae

AU - Lee, Kang Young

AU - Kim, Namkyu

AU - Chung, Hyuncheol

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Purpose: We investigated the prognostic factors for recurrence in Korean patients with stage II colon cancer and evaluated their predictive significance with 5-fluorouracil (FU)-based adjuvant chemotherapy. Methods: We analyzed the relationship between clinicopathological features and relapse-free survival (RFS) of 716 stage II colon cancer patients who underwent curative resection. Predictive values were assessed using 5-year RFS and 5-year cancer-specific survival (CSS). Results: The 5-year RFS, 5-year CSS, 5-year disease-free survival, and 5-year overall survival rates were 87.4, 94.9, 84.8, and 90.5 %, respectively. T4 stage (hazard ratio [HR], 2.342; 95 % confidence interval [CI], 1.348–4.068; p = 0.003), preoperative bowel obstruction or perforation (HR 2.428; 95 % CI 1.241–4.752; p = 0.010), and age older than 70 years (HR 1.740; 95 % CI 1.130–2.678; p = 0.012) were poor prognostic factors for recurrence in multiple Cox regression analyses. In 60 patients with T4 disease, 5-FU-based adjuvant chemotherapy was associated with improved 5-year CSS of the patients (90.3 vs. 46.7 %; HR 0.135; 95 % CI 0.035–0.517; p = 0.003). Conclusions: We found discordance between the risk factors for recurrence and the predictive value for 5-FU-based adjuvant chemotherapy in Korean patients with stage II colon cancer. Future prospective clinical trials selectively targeting high-risk patients are needed.

AB - Purpose: We investigated the prognostic factors for recurrence in Korean patients with stage II colon cancer and evaluated their predictive significance with 5-fluorouracil (FU)-based adjuvant chemotherapy. Methods: We analyzed the relationship between clinicopathological features and relapse-free survival (RFS) of 716 stage II colon cancer patients who underwent curative resection. Predictive values were assessed using 5-year RFS and 5-year cancer-specific survival (CSS). Results: The 5-year RFS, 5-year CSS, 5-year disease-free survival, and 5-year overall survival rates were 87.4, 94.9, 84.8, and 90.5 %, respectively. T4 stage (hazard ratio [HR], 2.342; 95 % confidence interval [CI], 1.348–4.068; p = 0.003), preoperative bowel obstruction or perforation (HR 2.428; 95 % CI 1.241–4.752; p = 0.010), and age older than 70 years (HR 1.740; 95 % CI 1.130–2.678; p = 0.012) were poor prognostic factors for recurrence in multiple Cox regression analyses. In 60 patients with T4 disease, 5-FU-based adjuvant chemotherapy was associated with improved 5-year CSS of the patients (90.3 vs. 46.7 %; HR 0.135; 95 % CI 0.035–0.517; p = 0.003). Conclusions: We found discordance between the risk factors for recurrence and the predictive value for 5-FU-based adjuvant chemotherapy in Korean patients with stage II colon cancer. Future prospective clinical trials selectively targeting high-risk patients are needed.

UR - http://www.scopus.com/inward/record.url?scp=84979591047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979591047&partnerID=8YFLogxK

U2 - 10.1007/s00432-016-2208-2

DO - 10.1007/s00432-016-2208-2

M3 - Article

C2 - 27447697

AN - SCOPUS:84979591047

VL - 142

SP - 2051

EP - 2059

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

IS - 9

ER -